BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

BioVox

January 19, 2017

New insights in genetic defect allow prevention of fatal illnesses in children

for BioVox

January 18, 2017

European patent attorney and biotech expert Caroline Pallard joins NLO patent office in Belgium

for BioVox

January 18, 2017

MDx Health ConfirMDx test covered by new insurance group

for BioVox

MDxHealth Announces Horizon Blue Cross Blue Shield of New Jersey Issues Positive Coverage Policy on ConfirmMDx. The decision provides access to more than 3.8 million members.

January 17, 2017

Medulloblastoma orphan drug designation for Oncurious

for BioVox

January 17, 2017

Market Access – the pitfall where innovations go lost

for BioVox

Market access is a crucial turning point for many companies. Getting your drug reimbursed by the government means the world. However, gaining market access [...]

January 17, 2017

Better together: R&D and GMP analytics teamed up at anaRIC Biologics

for BioVox

January 16, 2017

Coris Bioconcept diagnoses antibiotic resistance

for BioVox

With almost 20 years of experience, Coris BioConcept knows the world of infectious disease diagnostics inside and out. Their straightforward chromatography-based [...]

January 16, 2017

Legislators finally embrace in silico trials

for BioVox

In silico analysis is a natural complement to in vivo and in vitro testing. It uses engineering simulation to create reliable, computer-based models that predict [...]

January 16, 2017

PharmaFluidics raises 2.7 million euro to commercialize novel micro-chip device

for BioVox

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, announced today that it has raised 2.7 million euro of additional funding.

January 16, 2017

Survivors’s plasma to treat ebola patients does not meet expectations

for BioVox

Ebola Tx is the largest clinical study ever performed with blood plasma of people that survived Ebola, to treat the disease. The study was performed in Guinea by the Institute of Tropical Medicine (ITM) in Antwerp. The results of the study, which took place in 2015 during the Ebola epidemic, not only show that this treatment is feasible, but also that it presents no risk. The treatment causes very few side effects. However, the effectiveness needs to be further examined.